Gilead Tests Potential Ebola Treatment for Coronavirus
Gilead Sciences (GILD) announced that it is currently in the process of evaluating the use of its experimental Ebola candidate, Nuc inhibitor GS-5734, for treating 2019-nCov infection. The company is currently engaged in active discussions with clinicians and researchers in China and the United States.
China has currently put a couple of its cities on lockdown to arrest the spread of coronavirus. However, several cases of the ailment have been reported outside of China, thus sparking fears of a global outbreak. The US National Institute of